Alejandra Perez

5.4k total citations · 2 hit papers
30 papers, 1.6k citations indexed

About

Alejandra Perez is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics. According to data from OpenAlex, Alejandra Perez has authored 30 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 5 papers in Genetics. Recurrent topics in Alejandra Perez's work include Cancer Treatment and Pharmacology (13 papers), HER2/EGFR in Cancer Research (10 papers) and Advanced Breast Cancer Therapies (8 papers). Alejandra Perez is often cited by papers focused on Cancer Treatment and Pharmacology (13 papers), HER2/EGFR in Cancer Research (10 papers) and Advanced Breast Cancer Therapies (8 papers). Alejandra Perez collaborates with scholars based in United States, Japan and Canada. Alejandra Perez's co-authors include Hope S. Rugo, Charles L. Vogel, E. Shelley Hwang, Patricia A. Spears, Lisa A. Carey, Mark R. Somerfield, Neelima Denduluri, Rachel L. Yung, Dawn L. Hershman and Sibylle Loibl and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Alejandra Perez

29 papers receiving 1.6k citations

Hit Papers

Neoadjuvant Chemotherapy, Endocrine... 2014 2026 2018 2022 2021 2014 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
    2021 592 citations Larissa A. Korde, Mark R. Somerfield et al. Journal of Clinical Oncology profile →
  2. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2
    2014 407 citations Martine Piccart, Gabriel N. Hortobágyi et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alejandra Perez United States 12 842 611 588 493 164 30 1.6k
Ana C. Garrido-Castro United States 12 1.4k 1.7× 502 0.8× 474 0.8× 649 1.3× 144 0.9× 54 2.2k
Marianne Leheurteur France 15 816 1.0× 617 1.0× 285 0.5× 269 0.5× 113 0.7× 44 1.3k
Ying Fan China 23 1.1k 1.3× 513 0.8× 697 1.2× 542 1.1× 194 1.2× 120 1.7k
Huiqin Chen United States 21 1.0k 1.2× 543 0.9× 726 1.2× 1.1k 2.2× 170 1.0× 62 2.2k
Ricardo Costa United States 22 1.1k 1.4× 601 1.0× 540 0.9× 848 1.7× 177 1.1× 82 2.2k
Angel Rodriguez United States 21 770 0.9× 235 0.4× 609 1.0× 494 1.0× 193 1.2× 49 1.4k
Lars Damstrup Denmark 19 910 1.1× 452 0.7× 226 0.4× 902 1.8× 208 1.3× 43 1.9k
Qingyuan Zhang China 22 1.3k 1.6× 617 1.0× 331 0.6× 376 0.8× 291 1.8× 76 1.9k
Cesar A. Santa‐Maria United States 19 1.1k 1.3× 449 0.7× 646 1.1× 692 1.4× 235 1.4× 67 1.9k
Jianjun He China 27 837 1.0× 433 0.7× 846 1.4× 940 1.9× 82 0.5× 86 2.2k

Countries citing papers authored by Alejandra Perez

Since Specialization
Citations

This map shows the geographic impact of Alejandra Perez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alejandra Perez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alejandra Perez more than expected).

Fields of papers citing papers by Alejandra Perez

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alejandra Perez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alejandra Perez. The network helps show where Alejandra Perez may publish in the future.

Co-authorship network of co-authors of Alejandra Perez

This figure shows the co-authorship network connecting the top 25 collaborators of Alejandra Perez. A scholar is included among the top collaborators of Alejandra Perez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alejandra Perez. Alejandra Perez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Calfa, Carmen, et al.. (2022). Characterizing genitourinary exam disruptions in women presenting to a sexual health after cancer program.. Journal of Clinical Oncology. 40(16_suppl). e24048–e24048. 3 indexed citations
2.
Korde, Larissa A., Mark R. Somerfield, Lisa A. Carey, et al.. (2021). Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline. Journal of Clinical Oncology. 39(13). 1485–1505. 592 indexed citations breakdown →
3.
Perez, Alejandra, et al.. (2021). The Role of Health Literacy in Prostate Cancer Screening. Urology. 163. 112–118. 9 indexed citations
4.
O’Shaughnessy, Joyce, Kevin Punie, Mafalda Oliveira, et al.. (2021). Assessment of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) cohort by agent in the phase 3 ASCENT study of patients (pts) with metastatic triple-negative breast cancer (mTNBC).. Journal of Clinical Oncology. 39(15_suppl). 1077–1077. 7 indexed citations
5.
Rugo, Hope S., Kathleen I. Pritchard, Michael Gnant, et al.. (2014). Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2. Annals of Oncology. 25(4). 808–815. 93 indexed citations
6.
Piccart, Martine, Gabriel N. Hortobágyi, Mario Campone, et al.. (2014). Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. Annals of Oncology. 25(12). 2357–2362. 407 indexed citations breakdown →
7.
Hortobágyi, Gabriel N., Martine Piccart, Hope S. Rugo, et al.. (2013). Correlation of molecular alterations with efficacy of everolimus in hormone-receptor–positive (HR+), HER2-negative advanced breast cancer: Preliminary results from BOLERO-2.. Journal of Clinical Oncology. 31(15_suppl). LBA509–LBA509. 59 indexed citations
8.
Perez, Alejandra. (2013). Incidence, management, and resolution of stomatitis and noninfectious pneumonitis in BOLERO-2.. Journal of Clinical Oncology. 31(26_suppl). 159–159. 1 indexed citations
9.
Esteva, Francisco J., Sandra Franco, Abenaa M. Brewster, et al.. (2013). An Open-Label Safety Study of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2-Positive Metastatic Breast Cancer. The Oncologist. 18(6). 661–666. 15 indexed citations
10.
Perez, Alejandra, Hope S. Rugo, José Baselga, et al.. (2013). Clinical management and resolution of stomatitis in BOLERO-2.. Journal of Clinical Oncology. 31(15_suppl). 558–558. 3 indexed citations
11.
Buzdar, Aman U., Charles Vogel, Lee Schwartzberg, et al.. (2011). Randomized double‐blind phase 2 trial of 3 doses of TAS‐108 in patients with advanced or metastatic postmenopausal breast cancer. Cancer. 118(13). 3244–3253. 4 indexed citations
12.
Perez, Alejandra, Banu Arun, Debu Tripathy, et al.. (2010). A phase 1B dose escalation trial of Scutellaria barbata (BZL101) for patients with metastatic breast cancer. Breast Cancer Research and Treatment. 120(1). 111–118. 75 indexed citations
13.
14.
Rugo, Hope S., Emma Shtivelman, Alejandra Perez, et al.. (2006). Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancer. Breast Cancer Research and Treatment. 105(1). 17–28. 84 indexed citations
15.
Franco, Sandra, Alejandra Perez, Elizabeth Tan-Chiu, et al.. (2005). Preliminary results of a multicenter phase II trial of neoadjuvant docetaxel, carboplatin and capecitabine for inflammatory and locally advanced breast cancer (LABC). Journal of Clinical Oncology. 23(16_suppl). 876–876. 2 indexed citations
16.
17.
Franco, Sandra, et al.. (2004). Response to fulvestrant in heavily pretreated postmenopausal women:a single-center experience. Breast Cancer Research and Treatment. 88(2). 103–108. 27 indexed citations
18.
Salman, Huda, Alejandra Perez, Joseph A. Sparano, et al.. (2003). Phase II Trial of Infusional Cyclophosphamide, Idarubicin, and Etoposide in Poor Prognosis Non-Hodgkin’s Lymphoma. American Journal of Clinical Oncology. 26(4). 338–343. 1 indexed citations
19.
Perez, Alejandra, et al.. (2002). Pegylated Liposomal Doxorubicin (Doxil®) for Metastatic Breast Cancer: The Cancer Research Network, Inc., Experience. Cancer Investigation. 20(sup2). 22–29. 94 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ana C. Garrido-Castro Breakdown of academic impact, for papers by Marianne Leheurteur Breakdown of academic impact, for papers by Ying Fan Breakdown of academic impact, for papers by Huiqin Chen Breakdown of academic impact, for papers by Ricardo Costa Breakdown of academic impact, for papers by Angel Rodriguez Breakdown of academic impact, for papers by Lars Damstrup Breakdown of academic impact, for papers by Qingyuan Zhang Breakdown of academic impact, for papers by Cesar A. Santa‐Maria Breakdown of academic impact, for papers by Jianjun He
Rankless by CCL
2026